Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA ® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer ...
EYLEA HD has shown impressive durable visual improvements and rapid and resilient fluid control with a safety profile comparable to EYLEA Extended dosing intervals with EYLEA HD have the potential to ...
Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The findings, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback